Navigation Links
For the Treatment of Lupus, the Emerging Therapies Epratuzumab and Lupuzor Have the Potential to Offer Improvements Over IV Belimumab in Reducing Disease Activity
Date:4/2/2013

erceived to be modest and slow to onset."

The report also finds that physicians in the U.S. and Europe identify the need for new therapies with an improved effect on renal organ domain scores as a key unmet need. Therapies typically used for the treatment of moderate to severe renal manifestations (including the SLE-related condition of lupus nephritis) are associated with a risk of serious side effects. Interviewed thought leaders acknowledge that these therapies' overall risk-benefit profile is a limiting factor in their widespread use in patients with early and/or moderate signs of renal involvement.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...   The issue: ... confirmed it contains two undeclared amphetamine-like drug substances that ... Empire Health Distribution of Terrebonne, Quebec ... Canada .  Jetfuel Superburn is promoted ... increased energy. What consumers should do ...
(Date:12/24/2014)... -- Kinex Pharmaceuticals announced today that the first patient ... Institute. KX2-361 (KX02), a dual src/pre-tubulin inhibitor, ... inhibitory activity against a broad panel of brain tumor ... (T98G), the most widely used chemotherapy for the treatment ... model, KX2-361 consistently clears brain tumors after 4 weeks ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... Israel, December 20, 2011 During its meeting ... Governors of the Israel-U.S. Binational Industrial Research and Development ... new projects between Israeli and American companies. In addition to ... funding, boosting the total value of all projects to $22 ...
... a medical device company based in Worcester, MA developing ... Company,s $6 M Series B Preferred Stock offering closed ... been catalyzed by our technical progress and recent additions ... Scientific Advisory Board," explained Arthur Combs, Grove,s CEO. ...
Cached Medicine Technology:BIRD - Israel-US Binational Industrial R&D Foundation to Invest $8.1 Million in Nine new Projects 2BIRD - Israel-US Binational Industrial R&D Foundation to Invest $8.1 Million in Nine new Projects 3Grove Instruments Inc. Closes $6 M Series B Financing 2Grove Instruments Inc. Closes $6 M Series B Financing 3
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. TS-1 is an anti-cancer drug which ... administered orally and is also used for treating gastric ... gimestat and otastat potassium. The drug was first approved ...
(Date:12/25/2014)... 2014 Recently, Dylan Queen, a famous ... released its collection of discounted prom dresses, most of ... senior spokesman of the company, the promotion is valid ... is to expand the UK market. , The prom ... colors, lengths, and styles: A-line strapless, empire strapless chiffon, ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Helen Harris’ ... in Woodland Hills, California after an 8 year battle ... on Christmas Eve evening in her home in Woodland ... metastatic breast cancer. , As the ... forty years, she pioneered and championed many of today's ...
(Date:12/25/2014)... -- The risk of burns from fires and cooking ... be extra cautious, an expert says. "Between Thanksgiving ... in patients coming in with burns," said Dr. Steven ... Burn Center of Stony Brook University Hospital in New ... but if not careful, could quickly turn tragic," Sandoval ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the experience of ... has introduced its new collection of 2015 prom dresses, ... new prom outfits are guaranteed to contain the perfect ... specially designed for 2015. Anyone who wants to buy ... website before Jan. 26, 2015, the deadline of the ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Don't Let Burns Mar Your Holidays 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2
... even mild asthma among young inner-city children appears to be ... after diagnosis is a wise move as a hedge against ... according to a study from the Johns Hopkins Childrens Center. ... months after diagnosis, but six months may be too long ...
... Hopkins have evidence to explain why the supposedly natural act ... for life-threatening heart failure. , In a study ... (AHA) annual Scientific Sessions in Orlando, Fla., the Hopkins team ... pumping function to assess minute changes in the hearts of ...
... to do more to erase racial disparities, study suggests , ... pressure among heart failure patients vary widely by race and ... the Medical University of South Carolina, Mt. Pleasant, noted that ... but experts know little about actual rates of treatment and ...
... at AHA, including one from the Framingham Heart Study,link PAT ... ... ORLANDO, Fla., Nov. 4 Itamar Medical announced,confirmation of ... confirmation of PAT technology, Itamar Medical will now,promote clinical use ...
... increase the rate of coronary reperfusion (restoring blood flow ... the quality of care these patients received, according to ... coincide with its release at the American Heart Associations ... November 28 print issue of JAMA. , ST-segment ...
... Six Percent of Patients Discontinued Combination Therapy ... 4 New data released today,showed that ... proprietary extended-release niacin, Niaspan(R), and,simvastatin met its ... cholesterol minus HDL), while demonstrating improvements,on other ...
Cached Medicine News:Health News:Urban kids with asthma need more frequent check-ups, Hopkins study suggests 2Health News:Aging heart changes shape, shrinks and loses pumping function too 2Health News:Aging heart changes shape, shrinks and loses pumping function too 3Health News:Poorer Blood Pressure Control in Blacks With Heart Failure 2Health News:New Research Released at AHA Confirms Itamar's PAT Technology to Diagnose Early Cardiovascular Disease 2Health News:Statewide program helps improve quality of care for heart attack 2Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 2Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 3Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 4Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 5
... flexible lighting products. The first is available ... sizes 5", 10", and 15" (refers to ... These lights are for use in procedures ... second group of flexible lights is our ...
... Aaron manufactures two groups of flexible ... sterile and non-sterile in three different sizes ... flexible shaft portion of the light). These ... additional light is needed., ,The second ...
... toggle switches at off (center position) , ... pulses/10 s) , Tetanus: 50 Hz (50 pulses/s) ... (4 pulses/2 s); repeat (4 pulses/2 s; repeats ... 0-70 mA(HI range) 0-6.0mA (LO range) , Stimulus ...
... Operation: , Standby: A standby switch maintains power ... Twitch: 1 s (1 pulse/s) , Tetanus: ... pulses/2 s) , Output Current: Adjustable from 0-70 ... pulses (200-us duration) , Indicators: Battery LED (green) ...
Medicine Products: